Turn Therapeutics Inc. (TTRX) - Form 8-K Summary
Business Context and Reporting Period
Turn Therapeutics Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on May 11, 2026. The filing announces the financial and operating results for the quarter ended March 31, 2026. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol TTRX.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that a press release containing these details has been issued and is attached as Exhibit 99.1.
Material Changes
No material changes or comparative financial data are detailed within the body of this Form 8-K. The report references the attached press release for the full disclosure of results for the quarter ended March 31, 2026.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the information in Item 2.02 and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 11, 2026) for actual revenue, net loss, and cash position figures.
- Verify the specific operational milestones or clinical trial updates mentioned in the press release.
- Confirm the company's cash runway and burn rate as detailed in the full financial release.
- Check for any updated guidance regarding future product development timelines or regulatory filings.